Systematic differences between BNP immunoassays: Comparison of methods using standard protocols and quality control materials

Clinica Chimica Acta

Volumn 424, Issue , 2013, Pages 287-291

  Franzini, Maria ^a,b   Masotti, Silvia ^a   Prontera, Concetta ^b   Ripoli, Andrea ^b   Passino, Claudio ^a,b   Giovannini, Stefania ^c   Zucchelli, Giancarlo ^c   Clerico, Aldo ^a,b  

^a SCUOLA SUPERIORE SANT ANNA   (Italy)

^b Fondazione Toscana G Monasterio ^*  (Italy)

^c INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

BNP; Heart failure; Immunoassay; Method comparison; Quality control

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; EDETIC ACID;

ADULT; ANALYTICAL EQUIPMENT; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HEART FAILURE; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; ITALY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUALITY CONTROL;

BNP; HEART FAILURE; IMMUNOASSAY; METHOD COMPARISON; QUALITY CONTROL;

CASE-CONTROL STUDIES; HEART FAILURE; HUMANS; IMMUNOASSAY; ITALY; LABORATORIES; LIMIT OF DETECTION; NATRIURETIC PEPTIDE, BRAIN; OBSERVER VARIATION; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS;

EID: 84880984012     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.07.001     Document Type: Article

References (20)

1. Clerico A. Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: Are they merely markers of cardiac disease?. Clin Chem Lab Med 2002, 40:752-760.
2. Clerico A., Giannoni A., Vittorini S., Passino C. Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol 2011, 301:H12-H20.
3. Clerico A., Vittorini S., Passino C. Measurement of the pro-hormone of brain type natriuretic peptide (proBNP): methodological considerations and pathophysiological relevance. Clin Chem Lab Med 2011, 4:1949-1954.
4. Tang W.H., Francis G.S., Morrow D.A., et al. National Academy of Clinical Biochemistry Laboratory Medicine practicNICEe guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007, 116:e99-e109.
5. Dickestein K., Cohen-Solal A., Filippatos G., et al. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur J Heart Fail 2008, 10:993-89.
6. Yancy C.W., Jessup M., Bozkurt B., et al. ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol 2013, 10.1016/j.jacc.2013.05.019.
7. NICE, cinical guideline no 108. Chronic heart failure. National clinical guideline for diagnosis and management in primary and secondary care August 2010, 1-222.
8. Clerico A., Fontana M., Zyw L., et al. Comparison of the Diagnostic Accuracy of Brain Natriuretic Peptide (BNP) and the N-Terminal Part of the Propeptide of BNP Immunoassays in Chronic and Acute Heart Failure: A Systematic Review. Clin Chem 2007, 53:813-822.
9. Ewald B., Ewald D., Thakkinstian A., Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Intern Med J 2008, 38:101-113.
10. Liang F., O'Rear J., Schellenberger U., et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007, 49:1071-1078.
11. Seferian K.R., Tamm N.N., Semenov A.G., et al. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem 2007, 53:866-873.
12. Hammerer-Lercher A., Halfinger B., Sarg B., et al. Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure. Clin Chem 2008, 54:858-865.
13. Prontera C., Zaninotto M., Giovannini S., et al. Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the CardioOrmoCheck study. Clin Chem Lab Med 2009, 47:762-768.
14. Clerico A., Zaninotto M., Prontera C., et al. State of the art of BNP and NT-proBNP immunoassays: The CardioOrmoCheck study. Clin Chim Acta 2012, 414:112-119.
15. Rawlins M.L., Owen W.E., Roberts W.L. Performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol 2005, 123:439-445.
16. Apple F.S., Panteghini M., Ravkilde J., et al. Quality specifications for B-type natriuretic peptide assays. Clin Chem 2005, 51:486-493.
17. CLSI EP17-A protocol Protocols for determination of limits of detection and limits of quantitation; approved guidelines 2004, vol. 24, No. 34. [Wayne, Pennsylvania].
18. Prontera C., Storti S., Emdin M., et al. Comparison of a Fully Automated Immuno assay with a Point-of-Care Testing Method for B-Type Natriuretic Peptide. Clin Chem 2005, 51:1274-1276.
19. Emdin M., Passino C., Prontera C., et al. Comparison of Brain Natriuretic Peptide (BNP) and amino-terminal proBNP for early diagnosis of heart failure. Clin Chem 2007, 53:1289-1297.
20. Clerico A., Prontera C., Emdin M., et al. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma BNP and NT-proBNP concentrations. Clin Chem 2005, 51:445-447.